ZIMBABWE – Biotie Therapies Oyj (NASDAQ:BITI)‘s stock had its “outperform” rating reiterated by equities researchers at RBC Capital in a report issued on Monday, StockTargetPrices.com reports. They currently have a $35.00 target price on the stock. RBC Capital’s price target would suggest a potential upside of 135.85% from the company’s previous close.
A number of other research firms have also recently issued reports on BITI. Roth Capital initiated coverage on Biotie Therapies Oyj in a report on Tuesday, July 7th. They issued a “buy” rating and a $26.00 price objective on the stock. JMP Securities started coverage on Biotie Therapies Oyj in a report on Monday, July 6th. They set an “outperform” rating and a $32.00 price target on the stock. Stifel Nicolaus started coverage on Biotie Therapies Oyj in a research report on Monday, July 6th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Zacks downgraded Biotie Therapies Oyj from a “hold” rating to a “sell” rating in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Biotie Therapies Oyj currently has an average rating of “Buy” and a consensus price target of $30.75.
Biotie Therapies Oyj (NAZDAQ;BITI) traded down 6.27% during midday trading on Monday, reaching $13.91. 46,366 shares of the company’s stock traded hands. The stock’s market cap is $170.54 million. Biotie Therapies Oyj has a 52-week low of $13.67 and a 52-week high of $25.39. The company’s 50-day moving average price is $17.05 and its 200-day moving average price is $18.36.
Biotie Therapies Oyj (NASDAQ:BITI) last released its quarterly earnings results on Thursday, August 20th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by $0.67. On average, equities analysts predict that Biotie Therapies Oyj will post ($2.87) EPS for the current fiscal year.
Biotie Therapies Oyj is a Finland-based biopharmaceutical company, which specializes in the field of neurodegenerative and psychiatric disorders. Its product portfolio comprises six drugs: Selincro (NAZDAQ:BITI), an orally administered opioid receptor ligand applied in the alcohol dependence therapy; Tozadenant (SYN115), a is an oral, potent and selective adenosine 2a (A2a) receptor antagonist for the Parkinson’s disease treatment; NRL-1, a intranasal formulation of diazepam for patients with epilepsy; Nepicastat (SYN117), an orally administered, potent and selective inhibitor of dopamine beta hydroxylase (DBH) for the cocaine dependence treatment; BTT-1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 (VAP-1) used in inflammation and fibrosis treatment; and SYN120, an oral, potent and dual antagonist of the 5-HT6 and 5HT2a receptors used in Alzheimer’s disease and other cognitive disorders, such as schizophrenia. It is a parent of Biotie Therapies GmbH, among others.